A subscription to JoVE is required to view this content. Sign in or start your free trial.
* These authors contributed equally
Floating mammosphere assays can investigate the subset of stem-like breast cancer cells that survive in suspension conditions and show enhanced tumorigenesis when implanted into mice. This protocol provides a convenient in vitro measure of sphere-forming ability, a proxy for in vivo tumorigenesis, while facilitating analysis of the stem-associated transcriptional landscape.
Similar to healthy tissues, many blood and solid malignancies are now thought to be organised hierarchically, with a subset of stem-like cancer cells that self-renew while giving rise to more differentiated progeny. Understanding and targeting these cancer stem cells in breast cancer, which may possess enhanced chemo- and radio-resistance compared to the non-stem tumor bulk, has become an important research area. Markers including CD44, CD24, and ALDH activity can be assessed using fluorescence activated cell sorting (FACS) to prospectively isolate cells that display enhanced tumorigenicity when implanted into immunocompromised mice: the mammosphere assay has also become widely used for its ability to retrospectively identify sphere-forming cells that develop from single stem cell-like clones. Here we outline approaches for the appropriate culturing of mammospheres from cell lines or primary patient samples, their passaging, and calculations to estimate sphere forming efficiency (SFE). First we discuss key considerations and pitfalls in the appropriate planning and interpretation of mammosphere experiments.
The existence of tumor cell lineages headed by stem-like cancer stem cells has greatly added to our understanding of tumor heterogeneity. While some phenotypic diversity in tumors does arise from the clonal outgrowth of genetically distinct clones, a substantial component appears to result from epigenetic differences: cancer cells can transition (sometimes reversibly) between stem, progenitor, and differentiated states via activation or repression of specific gene expression programs1–3. This may reflect cell intrinsic or extrinsic factors, reflecting the gene expression program currently being expressed in a cell with its result....
The procedures below have been ethically approved by Imperial College, London.
1. Generation of Primary Mammospheres from Human Breast Cancer Cell Lines
NOTE: Perform the following steps under a sterile culture hood.
Different samples or those subjected to different treatments may vary in the number of mammospheres >40 µm that form after normalizing for initial cells seeded. Calculate mammosphere forming efficiency (MFE) for each treatment grown in triplicate. This enables experiments with different seeding densities to be compared. Data is best displayed on a bar graph, ideally with positive and negative controls, and displaying the standard deviation across the triplicate wells. Consistently transfer adherent cells into no.......
Successful assessment of primary and secondary mammospheres relies on cells being plated at sufficiently low densities that mammospheres form from single clones, with minimal sphere aggregation. However at densities that are too low, too few mammospheres may form to distinguish the effects of treatments statistically. Seeding density should be optimised for each cell line used since they can vary considerably in their sphere forming efficiencies (those expressing low E-cadherin may form less stable and shorter term mammo.......
This work is supported by the Imperial BRC, the National Institute for Health Research, and Action Against Cancer with special mention to Hilary Craft and Sir Douglas Myers.
....Name | Company | Catalog Number | Comments |
Name of Material/ Equipment | Company | Catalog Number | Comments/Description |
DMEM/F12 | Lonza | CC-3151 | |
2mM L-Glutamine | Sigma Aldrich | G8540 | |
100U/ml Penicillin & Streptomycin | Sigma Aldrich | P4083 | |
20ng/ml recombinant human epidermal growth factor (EGF) | Sigma Aldrich | E9644 | |
20ng/ml recombinant human basic fibroblast growth factor (bFGF) | R&D systems | 233-FB-025 | |
1x B27 supplement | Invitrogen | 17504-044 | |
Phosphate buffered saline (PBS); | Thermo Scientific | 12399902 | |
0.5% trypsin-0.2%EDTA; | Sigma Aldrich | 59418C | |
Fetal Calf Serum | First Link UK | 02-00-850 | |
Trypan Blue | Sigma Aldrich | 93595 | |
Low attachment 6 well plates | Corning | CLS3814 | |
Collagenase type 1A | Sigma Aldrich | C9891 | |
Hyaluronidase | Sigma Aldrich | H3506 | |
Sterile razor blades | Fisher Scientific | 12443170 | |
Sterile scalpel | Fisher Scientific | 11758353 | |
Sterile micro-dissecting scissors | Sigma Aldrich | S3146 |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved